Rare disease drugmakers, which have historically been better able to justify high prices than their peers, have recently ended up in the hot seat.

 

Gamida Cell & VBL Therapeutics to present at MIXiii Biomed.

Source: http://www.fiercepharma.com/pharma/no-scandal-here-say-rare-disease-drugmakers-as-pricing-scrutiny-lands-their-doorstep

JOIN OUR GROUP